- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00352807
Absorption of Brimonidine Ophthalmic Solution in the Aqueous Humor of Cataract Patients
October 16, 2007 updated by: Indiana University School of Medicine
Absorption of Brimonidine Ophthalmic Solution in the Aqueous Humor of Cataract Patients.
The purpose of this study is to obtain and assay human aqueous samples following pre-operative dosing with 0.1% Brimonidine Purite™ (pH 7.8) or with 0.15% Brimonidine Purite® (pH 7.2) from patients undergoing routine cataract surgery in order to evaluate the aqueous concentration of the two formulations.Study hypothesis: The aqueous humor concentration 45 minutes following dosing of 0.1% Brimonidine Purite™ (pH 7.8) is comparable with 0.15% Brimonidine Purite® (pH 7.2)
Study Overview
Detailed Description
The purpose of this study is to obtain and assay human aqueous samples following pre-operative dosing with 0.1% Brimonidine Purite™ (pH 7.8) or with 0.15% Brimonidine Purite® (pH 7.2) from patients undergoing routine cataract surgery in order to evaluate the aqueous concentration of the two formulations.
Study Type
Interventional
Enrollment
22
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- University Hospital
-
Indianapolis, Indiana, United States, 46202
- Wishard Memorial Hospital
-
Indianapolis, Indiana, United States, 46290
- IU Eye at Carmel
-
Indianapolis, Indiana, United States, 46202
- Veterans Affairs Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
All subjects must:
- Be willing and able to provide written Informed Consent
- Be able and willing to follow instructions and likely to complete the entire course of the study.
- Be male or female of any race at least 18 years of age.
- Have visually significant cataract for which they have elected to undergo cataract surgery.
Exclusion Criteria:
No subject may:
- Known allergy or sensitivity to the study medication or its components
- Contraindications to brimonidine therapy: concurrent use of monoamine oxidase (MAO) inhibitor therapy
- Have any active ocular disease other than glaucoma or ocular hypertension that would interfere with study parameters (such as: uveitis, ocular infection, or severe dry eye). Patients with mild chronic blepharitis, age-related macular degeneration, background diabetic retinopathy may be enrolled at the discretion of the investigator.
- Any ocular surgery (including laser, refractive, intraocular filtering surgery, or any other ocular surgery) within 3 months.
- Require use of ocular medications (including glaucoma medications), except intermittent use of artificial tears.
- Have corneal abnormalities that would interfere with the ability to obtain an adequate sample safely or have a shallow anterior chamber which would make obtaining an aqueous sample difficult at the time of surgery in the opinion of the investigator.
- Be concurrently enrolled in an investigational drug or device study or participation within the last 30 days in any investigational drug or device study.
- Be pregnant, nursing, planning a pregnancy, or be of childbearing potential and not using a reliable form of contraception.
- Have a situation or condition that in the investigator's opinion may put the subject at significant risk, may confound the study results, or may interfere significantly with participation in the study such as, significant cardiovascular disease, hepatic or renal impairment, depression, Raynaud's, orthostatic hypotension; uncontrolled high blood pressure. or concomitant use of other potential CNS depressants and tricyclics, (Amendment 1, May 25, 2005)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Bioanalysis of brimonidine concentrations.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Louis B Cantor, MD, IUPUI/Clarian
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- PK-02-P027 Relative ocular bioavailability of 0.2% Alphagan and 0.15% Brimonidine-BAK to that of 0.15% Alphagan P in female albino rabbits. Allergan 2002.
- PK-02-P041 Comparison of ocular and systemic bioavailability of three 0.10% brimonidine purite formulations to that of 0.15% Alphagan P in albino rabbits. Allergan 2002.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2005
Study Completion
December 1, 2005
Study Registration Dates
First Submitted
July 14, 2006
First Submitted That Met QC Criteria
July 14, 2006
First Posted (Estimate)
July 17, 2006
Study Record Updates
Last Update Posted (Estimate)
October 17, 2007
Last Update Submitted That Met QC Criteria
October 16, 2007
Last Verified
October 1, 2007
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0501-45
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cataract
-
Fundación Pública Andaluza para la Investigación...CompletedCataract | Cataract Mature | Cataract, Nuclear
-
Johannes Kepler University of LinzCompletedCataract Complicated | Cataract Complications OperationsAustria
-
Gemini Eye ClinicRecruitingBilateral Cataract | Unilateral CataractCzechia
-
Universitaire Ziekenhuizen KU LeuvenLaboratoires TheaRecruiting
-
Omer Othman AbdullahCompletedCongenital Cataract | Pediatric CataractIraq
-
Johannes Kepler University of LinzRecruitingAphakia | Secondary Cataract Surgery | Complicated Cataract SurgeryAustria
-
Yonsei UniversityCompletedCataract PatientsKorea, Republic of
-
Advanced Center for Eyecare GlobalNot yet recruiting
-
Vienna Institute for Research in Ocular SurgeryRecruiting
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityNot yet recruitingCataract ExtractionChina
Clinical Trials on Brimonidine Purite
-
Innovative MedicalCompletedGlaucomaUnited States
-
Northwestern Ophthalmic Institute S.C.Research to Prevent BlindnessCompletedPrimary Open Angle Glaucoma | Ocular HypertensionUnited States
-
Galderma R&DCompletedErythematous RosaceaUnited States
-
AllerganCompletedRetinitis PigmentosaFrance, United States, Germany, Portugal
-
Chulalongkorn UniversityCompleted
-
AllerganCompletedMacular DegenerationKorea, Republic of, Australia, Portugal, Germany, United States, Philippines, Italy
-
AllerganCompletedRhegmatogenous Macula-off Retinal DetachmentUnited Kingdom, Korea, Republic of, Israel, India, United States, Philippines
-
AllerganCompletedVitrectomyUnited States, Czech Republic
-
AllerganCompletedGlaucoma, Open-AngleIsrael, United States
-
Sun Pharma Advanced Research Company LimitedCompletedOcular Hypertension | Open Angle GlaucomaUnited States